This funding opportunity supports milestone-driven early stage clinical trials of novel investigational drugs and neuromodulatory devices targeting psychiatric disorders in pediatric and adult populations. It includes first in human and Phase II studies assessing brain exposure, pharmacological effects, safety, tolerability, and clinical impact. The goal is to de-risk novel treatments and foster collaborations between biomedical and industry researchers to accelerate development toward FDA approval.
Eligible applicants include state, county, city, and special district governments; federally recognized tribal governments; nonprofits with and without 501(c)(3) status; small businesses; public and private institutions of higher education; for-profit organizations other than small businesses; and i
